Furthermore, given that existing myosin inhibitors are tailored for cardiac myosins, the development of inhibitors specifically targeting skeletal myosins presents opportunities for the treatment of skeletal myopathies caused by mutations exclusively in skeletal myosins. This evidence concerns the gene MYH14 and Skeletal myopathy.